

Penelope Gray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1947872/publications.pdf>

Version: 2024-02-01

8
papers

103
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

77
citing authors

#	ARTICLE	IF	CITATIONS
1	Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1458-1468.	9.1	28
2	Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV). <i>International Journal of Cancer</i> , 2019, 145, 785-796.	5.1	20
3	Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. <i>BMJ Open</i> , 2021, 11, e050669.	1.9	16
4	Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage. <i>International Journal of Cancer</i> , 2020, 147, 3511-3522.	5.1	13
5	Baseline findings and safety of infrequent vs frequent screening of human papillomavirus vaccinated women. <i>International Journal of Cancer</i> , 2020, 147, 440-447.	5.1	8
6	Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003588.	8.4	8
7	In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers. <i>Expert Review of Vaccines</i> , 2022, 21, 735-738.	4.4	7
8	Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses. <i>Journal of Infectious Diseases</i> , 2022, 226, 1195-1199.	4.0	3